MEDIA CENTER

Executives from Frost & Sullivan: Policy support and full-seasonal innovation will drive new growth in China's ice and snow economy
Insights from Frost & Sullivan China's northern regions are witnessing a booming development of the ice and snow economy, with ice and cold weather becoming golden opportunities. Tourists are flocking to these areas, making the winter paradise once again a popular destination, and government policy
Explore more
Frost & Sullivan: The recovery of consumer electronics in 2025 is imminent, with AI and personalized customization becoming the core drivers
Frost & Sullivan insight Driven by large AI models, the AR glasses and consumer electronics industries are undergoing an intelligent transformation. Innovative applications empowered by AI and diverse needs are jointly driving rapid industry development, continuously unleashing market potential. Cur
Explore more
Executive from Frost & Sullivan: Hong Kong IPO market recovers significantly, policy optimization and industry hotspots drive future growth
Insights from Frost & Sullivan The Hong Kong Exchanges and Clearing Limited (HKEX) disclosed in its annual review that as of November 29, 2024, a total of 61 companies were newly listed on the HKEX, a year-on-year decrease of 16.4%. Despite the decline in the number of new listings, the amount raise
Explore more
Frost & Sullivan: Xiaomi's self-developed and self-manufactured air conditioners accelerate industry reshuffle, with intelligence and cost advantages becoming key competitive factors in the future
Insights from Frost & Sullivan Recently, Xiaomi has been making frequent moves in smart home appliances, with reports stating that "Xiaomi will be able to develop and produce its own air conditioners by 2025." What are the advantages of Xiaomi's self-developed and produced air conditioners? It is un
Explore more
Frost & Sullivan: The global ADC drug market is growing at a rapid pace, presenting Chinese innovative pharmaceutical companies with opportunities for differentiated competition
Recently, there have been continuous updates on the progress of domestic pharmaceutical companies in the field of antibody-drug conjugates (ADCs). On December 5th, Hengrui Medicine announced that the indication for its antibody-drug conjugate SHR-A2102 for urothelial cancer has been included in the
Explore more
Frost & Sullivan executive: Digital transformation helps energy companies improve collaboration efficiency and green, low-carbon development
What problems can traditional energy companies solve by building data centers? How can they assist in the green and low-carbon transformation and development of energy? How can traditional energy companies achieve a deep integration of industrial collaborative scheduling and digital transformation?
Explore more
Frost & Sullivan: Xpeng's Order for the Large-Scale Commercialization Accelerates the Commercialization Process and Lays the Foundation for Multi-Scenaried Applications
Pengfei Xpeng's flying car brand, Pegasus, achieved its first public flight as a 'land-based aircraft carrier' at the 15th China International Aerospace Expo and received new orders for 2,008 flying cars at this exhibition. This is the largest order volume in the global flying car sector to date, wi
Explore more
Frost & Sullivan: The NewCo model becomes a new frontier for innovative pharmaceutical companies to internationalize, with both opportunities and challenges
Recently, there have been continuous news about domestic innovative drugs going global: Merck & Co. has obtained the global exclusive license for its PD-1/VEGF bispecific antibody LM-299 for a upfront payment of $588 million; BioNTech has acquired 100% of the issued capital of Puma Biotech with an u
Explore more
Frost & Sullivan: "Innovation" and "going global" have become the "double engines" driving the advancement of the pharmaceutical and biotech industries
Explore more
Frost & Sullivan: CAR-T cell therapy expected innovation the treatment pattern
In recent years, CAR-T Cell therapy has achieved tremendous success in the field of tumor treatment and has become a powerful weapon against various malignant tumors. There are as many as six in China alone. CAR-T The product has been approved for market launch. Moreover, beyond oncology, an increas
Explore more
